BPC-157 vs Teduglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Body Protection Compound-157, Pentadecapeptide BPC 157
BPC-157 is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) based on a fragment of a protective protein found in human gastric juice. It is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. The catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof.
Also: Gattex, Revestive
Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome (SBS) in people who depend on IV nutrition or fluids. GLP-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. The FDA approved it as Gattex in December 2012 (children 1 year and older were added in 2019), and in Europe it is sold as Revestive. It works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement.
Key Comparison Insights
- Teduglutide is FDA approved, while BPC-157 remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Teduglutide has stronger research evidence (FDA Approved) compared to BPC-157 (Animal Studies).
Detailed Comparison
| Attribute | BPC-157 | Teduglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The leading hypothesis is that BPC-157 promotes new blood vessel growth by upregulating the VEGFR2 receptor, the same receptor that drives angiogenesis, and by tapping into the nitric oxide system through the Akt-eNOS pathway. Better blood supply to injured tissue would, in theory, speed healing of tendons, muscle, and gut lining. Animal work also points to anti-inflammatory effects and interaction with growth-factor signaling. It is worth being blunt here: these mechanisms are mostly worked out in rodents, and the exact molecular target of BPC-157 has never been definitively pinned down. Treat the pathway story as a well-supported hypothesis, not settled fact. | Teduglutide differs from natural GLP-2 by one amino acid (glycine swapped in at position 2), which shields it from DPP-4 breakdown and stretches its half-life from minutes to roughly 2 hours in healthy people (1.3 hours in SBS). It binds GLP-2 receptors on cells in the intestinal wall, which release local growth factors that increase villus height and crypt depth, improve blood flow to the gut, and slow gastric emptying and secretions. Net result: more absorptive surface and more time to absorb. The same growth signal is the reason for its main safety concern, because it can also speed the growth of polyps or existing tumors in the gut, so the label requires colonoscopy before and during treatment. |
| Common Dosing | 250-500 mcg twice daily 1-2x daily | 0.05 mg/kg once daily (labeled dose) Once daily |
| Administration | Subcutaneous injection near injury site, or systemic | Subcutaneous injection, rotating between abdominal quadrants, thighs, or arms |
| Typical Duration | 4-12 weeks in most research protocols | Long-term, with assessment of benefit and ongoing monitoring; IV support is weaned as absorption improves |
| Best Time to Take | Morning and evening (or near injury site timing) | Same time each day, any time of day |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The preclinical record is genuinely large. A 2025 narrative review in the journal Biomedicines counted hundreds of published animal studies showing BPC-157 accelerating healing across tendon, muscle, bone, gut, liver, and nervous-system injury models. The problem is the human side is nearly empty. That same review found only three published human pilot studies (knee pain injections, bladder injections for interstitial cystitis, and an intravenous safety trial) and concluded BPC-157 should be treated as investigational and not recommended for clinical use until proper trials exist. Pharmacokinetic work in rats and dogs found a very short elimination half-life (under 30 minutes after injection) and rapid breakdown into amino acid fragments, which raises real questions about how oral capsules sold online could deliver an intact peptide. Bottom line: lots of promising animal data, no completed randomized controlled trials in people, and no regulatory approval anywhere. | In the pivotal adult trial (Study 1, NCT00798967), 86 adults with SBS were randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. 63% on teduglutide versus 30% on placebo were responders (at least a 20% cut in weekly IV support at weeks 20 and 24), and weekly IV volume fell 4.4 L versus 2.3 L. In the 2-year open-label extension, 93% of the 30 patients who completed 30 months reached at least a 20% reduction, and a minority came off IV support entirely. An earlier trial (Study 3) used a different primary endpoint that missed at the higher dose, though responder rates at 0.05 mg/kg were 46% versus 6%. A 24-week pediatric study of 59 children aged 1 to 17 led to the 2019 approval: 69% on 0.05 mg/kg cut IV support by at least 20%, and 3 of 26 weaned off. Honest caveats: it is a lifelong therapy for most, benefits fade if stopped, and colon-in-continuity patients often respond less dramatically than those with a stoma. Longer-acting GLP-2 drugs (glepaglutide, apraglutide) are trying to replace the daily shot. |
Frequently Asked Questions: BPC-157 vs Teduglutide
What is the difference between BPC-157 and Teduglutide?
BPC-157 is a healing peptide that bpc-157 is a synthetic 15-amino-acid peptide (sequence gly-glu-pro-pro-pro-gly-lys-pro-ala-asp-asp-ala-gly-leu-val) based on a fragment of a protective protein found in human gastric juice. it is studied almost entirely in animals for tendon, ligament, gut, and tissue healing, and it has racked up hundreds of preclinical papers. the catch: it is not approved by any regulator for any use, and the human evidence is a handful of small pilot studies, not real clinical proof. Teduglutide is a healing peptide that teduglutide is a 33-amino-acid glp-2 analog approved for short bowel syndrome (sbs) in people who depend on iv nutrition or fluids. glp-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. the fda approved it as gattex in december 2012 (children 1 year and older were added in 2019), and in europe it is sold as revestive. it works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement. The main differences lie in their mechanisms of action and clinical applications.
Which is better, BPC-157 or Teduglutide?
Neither is universally "better" - the choice depends on your specific goals. BPC-157 is typically used for healing purposes, while Teduglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can BPC-157 and Teduglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using BPC-157 and Teduglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.